Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Dr Klaus Hellmann

Set Alert for Articles By Dr Klaus Hellmann

Latest From Dr Klaus Hellmann

European regulatory experts positive on current climate for novel therapies

Klifovet recently held a conference on the expectations of the Annex 2 proposal of Regulation 2019/6 in Munich, where a host of stakeholders from the European Medicines Agency, national regulatory agencies and the animal health industry attended. The contract research organization's chief executive Dr Klaus Hellman provided Animal Pharm with an overview of the pertinent topics covered.

Policy & Regulation Europe

How Brexit will impact the European and global animal health sectors

With the UK awaiting a hard or soft Brexit, many aspects of its EU divorce are still unknown. Klifovet is attempting to provide its clients with some regulatory clarity once Brexit is finalized. Dr Klaus Hellman gave Animal Pharm his point of view.

Europe United Kingdom

The clinically relevant endpoint: A crucial decision for successful efficacy studies

Dr Klaus Hellman, the chief executive of Klifovet, gives Animal Pharm an insight into the science and statistics behind clinical endpoints. This exclusive insight explains why is this data so crucial to the animal health sector.

Policy & Regulation Commercial
See All